Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog – Page 7895

Paris (AFP) — Scientists have observed the fifth state of matter in space for the first time, offering unprecedented insight that could help solve some of the quantum universe’s most intractable conundrums, research showed Thursday.

Bose-Einstein condensates (BECs) — the existence of which was predicted by Albert Einstein and Indian mathematician Satyendra Nath Bose almost a century ago — are formed when atoms of certain elements are cooled to near absolute zero (0 Kelvin, minus 273.15 Celsius).

At this point, the atoms become a single entity with quantum properties, wherein each particle also functions as a wave of matter.

Read more | >

“The operation is believed to be the first of its kind in the U.S. The patient, a woman in her 20s, had been healthy, but the coronavirus devastated her lungs.”

A young woman whose lungs were destroyed by the coronavirus received a double lung transplant last week at Northwestern Memorial Hospital in Chicago, the hospital reported on Thursday, the first known lung transplant in the United States for Covid-19.

The 10-hour surgery was more difficult and took several hours longer than most lung transplants because inflammation from the disease had left the woman’s lungs “completely plastered to tissue around them, the heart, the chest wall and diaphragm,” said Dr. Ankit Bharat, the chief of thoracic surgery and surgical director of the lung transplant program at Northwestern Medicine, which includes Northwestern Memorial Hospital, in an interview.

He said the patient, a woman in her 20s who had no serious underlying medical conditions, was recovering well: “She’s awake, she’s smiling, she FaceTimed with her family.”

Continue reading “Covid-19 Patient Gets Double Lung Transplant, Offering Hope for Others” | >

Regeneron Pharmaceuticals announced Thursday that it’s started the first clinical trial of its experimental coronavirus antibody drug.

The antibody cocktail is being tested in four human populations. Two groups of people will receive the drug to test its effectiveness as a treatment for Covid-19; the other two will receive it as a possible prevention.

“We’ll be hopefully to quickly test the safety and then start understanding the efficacy for four major different settings of this virus challenge,” Regeneron’s chief scientific officer, Dr. George Yancopoulos, said on CNBC’s “Squawk Box.” Yancopoulos said he thinks that, “if all goes well,” the company could have “definitive data” within a few months on the effectiveness of the antibody cocktail.

“I think there’s a lot of reason for hope,” Yancopoulos said, noting the company’s work on Ebola. But he also stressed the unpredictable nature of science and biology, saying “there’s always reasons to be concerned and to be cautious.” “So we’re going to be moving forward very carefully, hand-in-hand in with the FDA, and we hope sooner rather than later we can get answers that can really make a difference,” he said.

Regeneron is the latest company to begin trials for a potential Covid-19 therapy. Eli Lilly, which began trials of its antibody drug earlier this month, said a treatment could be authorized, if all goes well, for use as early as September. In scientific trials so far, Gilead Sciences’s antiviral remdesivir is the only drug to show some effectiveness in treating the disease. There are more than 7.4 million confirmed cases of Covid-19 in the world, including over 2 million in the U.S., according to the latest data from Johns Hopkins University. More than 417,100 people have died worldwide, with over a quarter of the fatalities in the U.S. Regeneron’s drug is being tested on four distinct types of patients, including “the sickest patients” who are hospitalized and on a ventilator or oxygen support, Yancopoulos said. It’s also being tested to see whether it can prevent high-risk people from contracting the disease, such as health-care workers. The drug, known as REGN-COV2, is a combination of two antibodies. Yancopoulos said Regeneron firmly believes this is the correct approach to treat Covid-19 when using antibodies.

Continue reading “Regeneron sees ‘a lot of reason for hope’ as human testing of its coronavirus drug begins” | >

Recent therapeutic trials of “classical” psychedelic drugs, such as psilocybin (from magic mushrooms) or LSD, have reported benefits to wellbeing, depression and anxiety. These effects seem to be linked to a sense of “ego dissolution” — a dissolving of the subjective boundaries between the self and the wider world. However, the neurochemistry behind this effect has been unclear. Now a new paper, published in Neuropsychopharmacology, suggests that changes in brain levels of the neurotransmitter glutamate are key to understanding reports of ego dissolution — and perhaps the therapeutic effects of psychedelics.

Natasha Mason at Maastricht University, the Netherlands, and colleagues recruited 60 participants for their study. All had taken a psychedelic drug before, but not in the three months prior to the study. Half received a placebo and the other half were given a low to moderate dose of psilocybin (0.17 mg/kg of body weight).

The team then used a technique called proton magnetic resonance spectroscopy (MRS) to look at concentrations of glutamate (as well as other neurochemicals) in the medial prefrontal cortex (mPFC) and the hippocampus — two regions that have been implicated as key to the psychedelic drug experience. The team also looked at patterns of “functional connectivity” within networks of brain regions, a measure of how closely correlated brain activity is across those regions. Six hours after taking the drug or placebo, the participants reported on their subjective experiences using two surveys: The 5 Dimensions of Altered States of Consciousness and the Ego Dissolution Inventory.

As the researchers expected (based on the findings of earlier research), those given the drug reported increased feelings of ego dissolution, as well as altered states of consciousness. They also showed disruptions in the connectivity of particular networks, including the default mode network, which has also been implicated in past work on the effects of psychedelic drugs…

But, for the first time in humans, the team also observed higher levels of glutamate in the mPFC and lower levels in the hippocampus after taking psilocybin — and they linked these changes to different aspects of ego dissolution. Increases in the mPFC were most strongly linked to unpleasant aspects, such as a loss of control over thoughts and decision-making, and also anxiety. Decreases in the hippocampus, meanwhile, were most strongly linked to more positive aspects, such as feelings of unity with the wider world, and of having undergone a spiritual-type experience.

Continue reading “Psilocybin Alters Brain Levels Of The Neurotransmitter Glutamate — And This Could Explain Why Users Experience “Ego Dissolution”” | >

Many consumers may have heard of blockchain technology, especially in relation to cryptocurrency. However, they may not be aware of its full potential and impact across industries. Blockchain has the potential to simplify and add greater security to data management, and since its inception, this technology has quietly been changing business processes.

To get further insights, we asked the members of Forbes Technology Council to share some ways blockchain has changed (or will soon change) business. Their best answers are below.

Photo:

Read more | >

Last week, I wrote about the diversity problem in AI and why we need to fix it. I asked you to tell us about your experiences as a Black person in AI or share the names of Black colleagues you admire. Thank you to everyone who responded. It was heart-warming to hear from so many of you.

Many of you shared your frustration with the lack of mentors who understand your challenges, the alienation of being the only Black face at professional meetings, and the struggle to overcome economic and social inequalities. Black women, especially, wrote about the difficulties of building a career in AI. Some of you described your efforts to support Black people in science and technology and provide tech resources to underserved communities. Thank you for sharing with us your dreams and also your disappointments.

We will feature some of your stories in our Working AI blog series. Please stay tuned.

Read more | >

A research team from ETH Zurich and the Max Planck Institute for Solar System Research in Göttingen counted over 136,000 rockfalls on the moon caused by asteroid impacts. Even billions of years old landscapes are still changing.

In October 2015, a spectacular rockfall occurred in the Swiss Alps: in the late morning hours, a large, snow-covered block with a volume of more than 1500 cubic meters suddenly detached from the summit of Mel de la Niva. It fell apart on its way downslope, but a number of continued their journey into the valley. One of the large boulders came to a halt at the foot of the summit next to a mountain hut, after traveling more than 1.4 kilometers and cutting through woods and meadows.

On the moon, time and again boulders and blocks of rock travel downslope, leaving behind impressive tracks, a phenomenon that has been observed since the first unmanned flights to the moon in the 1960s. During the Apollo missions, astronauts examined a few such tracks on site and returned displaced rock block samples to Earth. However, until a few years ago, it remained difficult to gain an overview of how widespread such rock movements are and where exactly they occur.

Read more | >